The Role of IFNE Gene Alterations in Predicting Clinical Outcomes in Brain Cancer: A Multi-Study Analysis
Gerald Hyunwoo Kang
United World College of South East Asia Dover, Singapore
Publication date: September 19, 2024
United World College of South East Asia Dover, Singapore
Publication date: September 19, 2024
DOI: http://doi.org/10.34614/JIYRC202407
ABSTRACT
Brain cancer is a critical global health issue, ranking 12th in the leading causes of cancer deaths. This study analysed 23,698 genes across 898 brain cancer patients in 26 studies, utilising cBioPortal’s data to identify the top 20 most frequently altered genes in deceased patients. This study thus aimed to find a novel gene that could affect brain cancer patients’ survival outcomes, where five interferon (IFN) genes were identified out of the initial 20, with interferon-epsilon (IFNE) genes having the highest alteration frequency. Further IFNE gene analysis indicated a significant association with tumour grade and overall survival rates of brain cancer patients; deep deletion of IFNE genes was predominantly observed in Grade IV tumours and associated with poorer survival outcomes. Specifically, the Grade IV tumours had a disproportionate 93.48% of the cases exhibiting deep-deletions, discernibly contrasting with the Grade II and III tumours, at 3.26% respectively, and the IFNE altered group’s median survival being 14.49 months, whilst the unaltered group’s median survival was 31.10 months. These findings present a potential for IFNE genes as a prognostic biomarker and target for gene therapy in brain cancer
Brain cancer is a critical global health issue, ranking 12th in the leading causes of cancer deaths. This study analysed 23,698 genes across 898 brain cancer patients in 26 studies, utilising cBioPortal’s data to identify the top 20 most frequently altered genes in deceased patients. This study thus aimed to find a novel gene that could affect brain cancer patients’ survival outcomes, where five interferon (IFN) genes were identified out of the initial 20, with interferon-epsilon (IFNE) genes having the highest alteration frequency. Further IFNE gene analysis indicated a significant association with tumour grade and overall survival rates of brain cancer patients; deep deletion of IFNE genes was predominantly observed in Grade IV tumours and associated with poorer survival outcomes. Specifically, the Grade IV tumours had a disproportionate 93.48% of the cases exhibiting deep-deletions, discernibly contrasting with the Grade II and III tumours, at 3.26% respectively, and the IFNE altered group’s median survival being 14.49 months, whilst the unaltered group’s median survival was 31.10 months. These findings present a potential for IFNE genes as a prognostic biomarker and target for gene therapy in brain cancer
